Holen Sie sich die Stockscreener-App
64.15
1.33%
0.8904
Schlusskurs vom Vortag:
$63.26
Offen:
$63.95
24-Stunden-Volumen:
19,364
Relative Volume:
0.02
Marktkapitalisierung:
$4.44B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-16.24
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
+13.44%
1M Leistung:
+21.54%
6M Leistung:
+55.92%
1J Leistung:
+15.45%
1-Tages-Spanne:
$62.78
$64.88
1-Wochen-Bereich:
$56.91
$64.88
52-Wochen-Spanne:
$33.19
$64.88
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
64.10 | 4.10B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.41 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.58 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.94 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.93 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.32 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-21 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-03-28 | Eingeleitet | Truist | Buy |
| 2024-03-04 | Bestätigt | Needham | Buy |
| 2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-08-21 | Eingeleitet | TD Cowen | Outperform |
| 2022-08-02 | Eingeleitet | Stifel | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Needham | Buy |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-08 | Eingeleitet | William Blair | Outperform |
| 2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Buy |
| 2019-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Fortgesetzt | Guggenheim | Buy |
| 2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-06-13 | Eingeleitet | Citigroup | Buy |
| 2016-06-13 | Eingeleitet | Guggenheim | Buy |
| 2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
What analysts say about Merus N.V. stockMarket-leading profit generation - Autocar Professional
Merus N.V. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com
What drives Merus N.V. stock pricePhenomenal trading returns - Autocar Professional
Is Merus N.V. a good long term investmentRapidly expanding wealth - Autocar Professional
Merus Shares Soar 3.24% On Positive Cancer Study Update - AInvest
Merus NV stock hits all-time high, reaching 62.98 USD - Investing.com
Merus Shares Surge Amid Promising Cancer Study - TipRanks
Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study - TipRanks
Learn to Evaluate (MRUS) using the Charts - news.stocktradersdaily.com
Merus N.V. (NASDAQ:MRUS) Shares Sold by Teacher Retirement System of Texas - Defense World
Merus N.V. (NASDAQ:MRUS) Given Average Rating of “Buy” by Analysts - Defense World
Why Merus N.V. stock attracts strong analyst attentionFree Access to Community - Newser
How Merus N.V. stock performs during market volatilitySwing Trade Signals - newser.com
Merus (MRUS) Gets a Buy from H.C. Wainwright - The Globe and Mail
What makes Merus N.V. stock price move sharplyAlpha Stock Ideas - Newser
Insider Selling: Merus N.V. (NASDAQ:MRUS) COO Sells $924,275.00 in Stock - Defense World
Merus (NASDAQ:MRUS) Upgraded by Wall Street Zen to Hold Rating - Defense World
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success - sharewise.com
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Insider Monkey
Merus N.V.: Making Progress (NASDAQ:MRUS) - Seeking Alpha
Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know - TipRanks
Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN
(MRUS) Technical Data - news.stocktradersdaily.com
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential - Investing.com India
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential By Investing.com - Investing.com South Africa
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha
The Netherlands: Merus raises US$300m from underwritten public offering - Investors in Healthcare
Why Merus N.V. (MRUS) Crashed On Wednesday - MSN
Merus N.V. announces proposed public offering of common shares - MSN
Merus dips 7%, prices $300M stock at $57 per share - MSN
Merus Announces Public Offering of Common Shares - TipRanks
Merus Raises $300m After ASCO Success - insights.citeline.com
Sector Update: Health Care Stocks Mixed Premarket Wednesday - marketscreener.com
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Merus N V-Aktie (MRUS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
4.56%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):